2013
Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages
Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Science 2013, 104: 1027-1032. PMID: 23710822, PMCID: PMC7657257, DOI: 10.1111/cas.12206.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen Receptor AntagonistsAndrogensAnilidesAnimalsBenzamidesBenzofuransBone Morphogenetic Protein 6Cell Line, TumorDihydrotestosteroneHumansInterleukin-6Lymphocytes, Tumor-InfiltratingMacrophagesMaleMiceNitrilesPhenylthiohydantoinPromoter Regions, GeneticProstatic Neoplasms, Castration-ResistantQuinolinesReceptors, AndrogenTosyl CompoundsUp-RegulationConceptsCaP cell linesCastration resistanceInterleukin-6Castration-resistant prostate cancerContext of macrophagesHuman CaP cell linesExpression of ARRemoval of macrophagesAndrogen receptor mRNAProstate cancer progressionBMP-6Presence of dihydrotestosteroneProstate cancer cellsCell linesPresence of macrophagesPleiotropic growth factorBone morphogenetic proteinClodronate liposomesTRAMP-C1AR upregulationProstate cancerAndrogen hypersensitivityMacrophage coculturesReceptor mRNACell count
2012
CREBZF, a novel Smad8-binding protein
Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein. Molecular And Cellular Biochemistry 2012, 368: 147-153. PMID: 22707059, DOI: 10.1007/s11010-012-1353-4.Peer-Reviewed Original ResearchConceptsSmads 1Novel SmadTranscription factorsBMP-6Basic region-leucine zipper (bZIP) transcription factorsBone morphogenetic protein (BMP) pathwayRegulation of SmadTwo-hybrid screeningModulation of BMPBMP response elementZipper transcription factorTGF-β signal pathwayR-SmadsReceptor SmadsBMP pathwaySecondary messengersPromoter activityLigand bindingProtein pathwayResponse elementProstate cancer cell linesCell growth inhibitionHuman prostate cancer cell linesSmadSignal pathwayRas Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier
2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumorsEFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research 2011, 17: 4523-4530. PMID: 21571867, DOI: 10.1158/1078-0432.ccr-10-2817.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAzacitidineBiomarkers, TumorCell Line, TumorCpG IslandsDecitabineDNA MethylationDNA Modification MethylasesEpigenomicsExtracellular Matrix ProteinsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPromoter Regions, GeneticProstatic HyperplasiaProstatic NeoplasmsReproducibility of ResultsConceptsEpidermal growth factor-containing fibulin-like extracellular matrix protein 1DNA methylationGene Expression OmnibusExpression profilingProstate cell linesGenome-wide characterizationCell linesMethylation statusExtracellular matrix protein 1Methylation markersDNA methylation profilesBisulfite sequencing analysisFibulin-like extracellular matrix protein 1Aberrant methylation patternsAbnormal DNA methylationExpression levelsNovel methylation markersGene expression analysisGene expression profilingNovel DNA methylation markersMatrix protein 1Gene expression dataGene expression levelsMicroarray gene expression dataMethylation patterns
2000
Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor
Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor. The Prostate 2000, 43: 118-124. PMID: 10754527, DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsApoptosisGenes, DominantGenomeImmunohistochemistryMaleMiceMice, TransgenicOrgan SizePromoter Regions, GeneticProstateProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptors, AndrogenReceptors, Transforming Growth Factor betaTestosteroneConceptsVentral prostateEpithelial cellsAnimal prostatesDominant negative receptorTransgenic miceNegative receptorProstate-specific promotersProstatic epithelial cellsTransgenic mouse systemTGF-beta resultsSerum levelsTGF-beta signalingProstate growthProstatic growthNormal prostateAndrogenic statusProstateProximal ductExperimental modelLoss of apoptosisInhibitory effectMouse systemSignificant differencesAbnormal morphologyLoss of sensitivity
1996
Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.Peer-Reviewed Original ResearchMeSH KeywordsBinding, CompetitiveCell CountCell DivisionDihydrotestosteroneDNA, NeoplasmHumansMalePromoter Regions, GeneticProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTranscriptional ActivationTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta receptor type IILNCaP cellsReceptor type IIAndrogen-responsive prostate cancerCharcoal-stripped fetal bovine serumEffect of dihydrotestosteroneGrowth factor-β1Type II TGF-β receptorProstate cancer cellsGrowth inhibitory effectsTGF-β receptorWestern blot analysisDHT concentrationsPresent studyType IIModulation of sensitivityProstate cancerAndrogenic conditionsFactor-β1DihydrotestosteronePotential physiological regulatorsInhibitory effectGene transcriptional activityCancer cellsPhysiological regulator